Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Dasatinib combined with CAR T-cell therapy demonstrates encouraging efficacy and acceptable toxicity as frontline treatment for newly diagnosed Philadelphia chromosome–positive ALL.
In this phase 2, single‑arm, nonrandomized clinical trial that included 28 adults with Ph‑positive ALL, the complete molecular remission rate after CD19 CAR T‑cell therapy was 85 %. This treatment showed a good safety profile, with only grade 1 cytokine release syndrome and no neurotoxic effects.
Combining dasatinib with CAR T‑cell therapy could improve remission rates and reduce toxicity in newly diagnosed Ph‑positive ALL, offering a potentially more effective frontline treatment.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- Recent advances on blinatumomab for acute lymphoblastic leukemia
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia